Diabetes

Generic semaglutide market shows signs of excess inventory bulge

Distributors grapple with rising semaglutide inventory amid slower liquidation

Dexcom's glucose monitor use benefits non-insulin diabetic patients: Study

Participants using the Dexcom G7 saw an average 1.6% reduction in their blood sugar levels at 26 weeks, a 0.9% greater reduction than those who used self-monitoring

Alkem launches semaglutide pre-filled syringes in India at ₹350

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

Best of BS Opinion: HDFC Bank must emphatically address all concerns

Hello and welcome to BS Opinion, a wrap of editorials and columns on today's Opinion page

Improving health outcomes: Survey suggests the need for a holistic approach

NFHS-6 shows gains in child nutrition and healthcare access, but rising obesity and diabetes underscore the need for a more comprehensive public health strategy

Worsening side effects of life in fast lane: Obesity, diabetes up sharply

Lifestyle diseases on the rise, shows NFHS-6, though insurance coverage, vaccination rates, maternal care, child health indicators have improved

India's pharma market grows 10.3% in April on strong chronic performance

India's pharmaceutical market grew 10.3 per cent in April, led by strong demand for anti-diabetes, cardiac and respiratory therapies

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Alembic Pharma receives USFDA approval for generic dapagliflozin tablets

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets used to control blood sugar levels in people with type-2 diabetes. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of dapagliflozin tablets of strengths 5 mg and 10 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca), it added. Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. With this approval, Alembic is eligible for 180 days of shared generic drug marketing exclusivity, the company said. Dapagliflozin tablet is indicated to reduce the risk of hospitalisation for heart failure in adults with ...

Cheap, accessible, powerful: The promise and peril of semaglutide in India

Cheap, accessible, and powerful semaglutide is changing India’s weight-loss and diabetes landscape. But as prices crash and access expands, the risks also increase

Govt issues guidelines on GLP-1 drugs use, risks, and regulations

To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect

Aurobindo gains 3%, stock hits 52-week high; JM Financial sees more upside

In the past one month, Aurobindo has outperformed the market by surging 9 per cent, as compared to 8.5 per cent decline in the BSE Sensex.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Semaglutide prices crash up to 90% as 15+ generics launch in two days

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Delhi HC seeks response from Centre, CDSCO over misuse of diabetes drugs

These drugs, though approved for type 2 diabetes, have witnessed a surge in demand globally due to their weight-loss effects

Study links fathers' nicotine use to altered metabolism in children

A new mouse study suggests nicotine exposure in fathers before conception may alter how their children process sugar and metabolism, potentially raising diabetes risk in the next generation

GLP-1 drugs may fight addiction across every major substance: Study

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction

Novo Nordisk, Abbott tie up to launch second Ozempic brand in India

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry